Reig Jofre reduces profits. The Catalan drugmaker posted a profit of $4.17 million (€3.5 million) in the first half of 2021, which translates into a 7.7% decrease compared with the same period in 2020, the group reported on July 29th in a statement sent to the National Securities Market Commission (Cnmv).
The pharma company closed the first half of the year with sales of $138 million (€116 million), which represents a slightly higher figure than the first half of 2020. This period was the peak in the consumption of hospital drugs due to the needs derived, in particular, from patients admitted to the ICU.
Due to the lower weight in sales of essential medicines, which have a lower margin, and growth in specialty pharmacare and consumer healthcare, the gross margin stood at 62%, two points higher than in the same period of 2020.
Some ranges achieved growth in this context, offsetting the impact of lower demand for antibiotics and OTC products as a result of social distancing measures. Gross operating profit (Ebitda) increased by 3% to $15.8 million (€13.3 million).
Read more on the subject and find the latest financial news in the world with our companion app Born2Invest
Reig Jofre achieved Ebitda of $15.8 million €13.3 million) in the first half of 2021
Personnel expenses rose by 3%, essentially due to the incorporation of technical personnel at the new injectables plant. Other operating expenses increased by 4%, due to expenses associated with the new plant.
Commercial and marketing expenses, which remain contained but are already showing some growth, “will be carefully managed in line with the evolution of revenues,” Reig Jofre explained in its note.
Investments in technology and capacity expansion in 2021 amounted to $10.5 million (€8.8 million) in the first half of the year. This essentially corresponds to two projects: a comprehensive renovation of facilities at the Toledo factory and the adaptation of the Barcelona plant for the manufacture of the Covid-19 vaccine. In addition, $2.74 million (€2.3 million) have been activated, corresponding to the progress during 2021 of ongoing research and development (R&D) projects.
Grifols’ first-half profit rises 22% to $317.7 million (€267 million)
Grifols increases its profits in the first six months of the year. The Spanish multinational, which specializes in the production of plasma derivatives, achieved a profit of $317.5 million (€266.8 million) in the first half of 2021, which translates into an increase of 22.3% compared to the same period in 2020. Adjusted net profit amounted to $332.1 million (€279.1 million).
These results are justified by the gradual recovery of plasma supply levels, the raw material needed to produce drugs. In a half-year period marked by the gradual recovery of plasma donations, debt reduction, and a major investment effort to continue boosting plasma supply levels and innovation, Grifols’ turnover stood at $3 billion (€2.54 billion), representing an increase of 2.3% compared to the same period in 2020.
In the second quarter of 2021, revenues grew by 5.3% to $1.6 billion (€1.35 billion) driven by the positive performance of the main business lines of the bioscience, diagnostic, and hospital divisions.
Grifols achieved Ebitda of $700 million (€634.5 million) in the first half of 2021
The gross margin stood at 43.9% in the first half of 2021 compared to 38.8% reported in the same period of 2020, while in the second quarter it amounted to 43%. Gross operating profit (Ebitda) stood at €634.5 million (€337.7 million) in the second quarter), up 9.4% over the six-month period.
The Ebitda margin was 25% of revenues (25.1% in the first quarter). Grifols maintains its plan to contain operating costs by $118 million (€100 million) per year, which, without impacting its efforts in innovation, “is allowing it to optimize the management of Grifols’ economic performance,” the company explained in a statement sent to the Spanish Securities and Exchange Commission (CNMV).
Grifols has ratified its commitment to innovation, which combines its expertise in plasma medicines with the progressive strengthening of a complementary portfolio of non-plasma products. In this context, total net investment in research, development, and innovation (R&D&I) amounted to $185 million (€155.3 million), representing 6.1% of revenues
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Modern Monetary Theory Has no Place for Supply and Demand Fundamentals
All big market declines in the Dow Jones occurred with all-time highs in Dow Jones trading volume. A complete inversion...
Cosmos Price Forecast After ATOM Shoots Into Top 20
Cosmos price is recovering due to the general demand for altcoins. In fact, a closer look at CoinMarketCap shows that...
Post-COVID-19, Business Risk Assessments Look Different for Investors
When conducting a business risk assessment, investors dig deeply into a company’s inner workings to predict whether it will be...
Encomenda Invests €200,000 to Launch Telemedicine Startup Doctomatic
The fund led by Carlos Blanco and Oriol Juncosa has helped launch this new digital platform, called Doctomatic, for remote...
Burkina Faso: The European Investment Bank Strengthens its Partnership with CAPE
According to the Director-General of CAPE Burkina, the support of the EIB is one of the major factors that has...
Cannabis2 weeks ago
Are Cannabis Social Clubs in Barcelona on the Verge of Closure
Featured2 weeks ago
Should You be Looking for Reasons to Sell the Stock Market
Africa2 weeks ago
Energy Efficiency: the Moroccan Ministry of Housing Gets up to Standards
Crypto2 weeks ago
Coinbase Pro Accidentally Relists the Troubled XRP